Latest revenue
$191.2M
as of 2026-03-31
Latest net income
$-64.5M
as of 2026-03-31
Net margin
-33.8%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $12.14B
- Enterprise value
- $12.14B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $236.84
- 52-wk low
- $96.09
- Beta
- —
- Shares out
- 51.5M
5-year trend
What this company does
ITEM 1. BUSINESS. OVERVIEW We are a fully integrated biopharmaceutical company focused on developing innovative medicines for people impacted by central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and developing differentiated products with a focus on novel mechanisms of action, that have the potential to transform patient outcomes. Our innovative CNS portfolio is anchored by three U.S. Food and Drug Administration (FDA) approved commercial products: AUVELITY® for the treatment of major depressive disorder (MDD), SUNOSI® for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea or narcolepsy,…
AI summary unavailable — showing raw filing excerpt
Generated from AXSM's filing dated 2026-02-23
Key risks
K FACTORS. The Company is subject to a number of risks that if realized could materially adversely affect its business, results of operations, cash flow, financial condition or prospects. The following is a summary of the principal risk factors facing the Company. The list below is not exhaustive, and the Company faces additional challenges and risks. Investors should carefully consider all of the information set forth in this Annual Report on Form 10-K, including the following risk factors, before deciding to invest in any of the Company’s securities. Risk Factors Summary Our business is subject to a number of risks and uncertainties, including those risks discussed at length below. These…
AI summary unavailable — showing raw filing excerpt
Generated from AXSM's filing dated 2026-02-23
Profitability
Operating margin
-26.1%
64.1%Net margin
-28.7%
61.5%Return on equity
-207.5%
58.8%Return on assets
-26.6%
47.4%Leverage
Debt / equity
6.81×
24.1%Long-term debt / equity
1.33×
57.9%Debt / assets
87.2%
3.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $191.2M | +57.4% | $-64.5M | -8.6% | -33.8% |
Q4 2025 2025-12-31 | $196.0M | +65.0% | $-28.6M | +61.9% | -14.6% |
Q3 2025 2025-09-30 | $171.0M | +63.2% | $-47.2M | +26.9% | -27.6% |
Q2 2025 2025-06-30 | $150.0M | +72.1% | $-48.0M | +39.5% | -32.0% |
Q1 2025 2025-03-31 | $121.5M | +62.0% | $-59.4M | +13.1% | -48.9% |
Q4 2024 2024-12-31 | $118.8M | — | $-74.9M | — | -63.1% |
Q3 2024 2024-09-30 | $104.8M | +81.3% | $-64.6M | -3.9% | -61.7% |
Q2 2024 2024-06-30 | $87.2M | +86.7% | $-79.3M | -18.1% | -91.0% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on AXSM — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$200.5K
Insider selling
$130.5M
Net activity
−$130.3M
Distinct insiders
8
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AXSM
Institutional value
$3.06B
Total shares held
18.2M
Distinct holders
240
-154 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 3.9M | $661.3M | -699 (-0.0%) | Trimmed |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.1M | $347.9M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 1.9M | $327.5M | — | New |
| 4 | Invesco Ltd. | 1.3M | $219.3M | +24.2K (+1.9%) | Added |
| 5 | Assenagon Asset Management S.A. | 866.0K | $146.4M | +398.0K (+85.0%) | Added |
| 6 | ALETHEA CAPITAL MANAGEMENT, LLC | 649.1K | $109.7M | -19.6K (-2.9%) | Trimmed |
| 7 | FIRST TRUST ADVISORS LP | 577.5K | $97.6M | +534.1K (+1230.2%) | Added |
| 8 | UBS Group AG | 547.2K | $92.5M | +191.9K (+54.0%) | Added |
| 9 | FRANKLIN RESOURCES INC | 438.5K | $74.1M | +95.9K (+28.0%) | Added |
| 10 | Pictet Asset Management Holding SA | 416.0K | $70.3M | -20.1K (-4.6%) | Trimmed |
| 11 | PRINCIPAL FINANCIAL GROUP INC | 350.5K | $59.2M | -12.6K (-3.5%) | Trimmed |
| 12 | Nuveen, LLC | 335.7K | $56.7M | -13.5K (-3.9%) | Trimmed |
| 13 | VANGUARD FIDUCIARY TRUST CO | 295.1K | $49.9M | — | New |
| 14 | JPMORGAN CHASE & CO | 270.2K | $43.4M | +37.0K (+15.9%) | Added |
| 15 | Bank of New York Mellon Corp | 206.6K | $34.9M | -48.5K (-19.0%) | Trimmed |
| 16 | BNP PARIBAS FINANCIAL MARKETS | 188.1K | $31.8M | -116.2K (-38.2%) | Trimmed |
| 17 | CITIGROUP INC | 185.7K | $31.4M | -18.4K (-9.0%) | Trimmed |
| 18 | Voya Investment Management LLC | 184.0K | $31.1M | +10.7K (+6.2%) | Added |
| 19 | abrdn plc | 149.7K | $25.3M | +52.3K (+53.7%) | Added |
| 20 | Connor, Clark & Lunn Investment Management Ltd. | 134.8K | $22.8M | -53.5K (-28.4%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AXSM's latest filing finishes processing.